Clinical Trial Update: Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability and symptomatic efficacy of the ROCK inhibitor fasudil in patients with Parkinson's disease; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• fasudil (fasudil)

Snippet

Sponsor: Technical University of Munich | Conditions: Idiopathic Parkinson´s Disease | Phase 2 | Status: RECRUITING